Technology Offerings

New Somatostatin Substances Target Neuropathic Pain Relief

Neuropathic pain is rather resistant

to conventional analgesics. Therefore, different approaches must be taken to treat neuropathic pain. One possibility is the use of agents acting at the level of the sensory nerve terminals themselves to inhibit the release of these pro-inflammatory/pronociceptive sensory neuropeptides. Such agents may form the basis for the development of a new group of anti-inflammatory and analgesic drugs. In this invention Somatostatin-derived substances were developed that can inhibit inflammation without accompanying endocrine side effects. Furthermore they exhibit satisfactory half life and bioavailability, especially after oral administration.

Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

Comments (0)

Write a comment